Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(2):316–322. doi: 10.1038/sj.bjc.6990694

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast

C Harper-Wynne 1, J English 1, L Meyer 2, M Bower 1, C Archer 1, H D Sinnett 3, C Lowdell 4, R C Coombes 1
PMCID: PMC2362871  PMID: 10496359

Abstract

One hundred and sixteen patients with locally advanced or metastatic breast cancer were randomized to receive CMF (cyclophosphamide 600 mg m−2 day 1 and 8 i.v., 5-fluorouracil 600 mg m−2 day 1 and 8 i.v.,, methotrexate 40 mg m−2 day 1 and 8 i.v., monthly for 6 cycles) or MM (methotrexate 30 mg m−2, mitoxantrone 6.5 mg m−2, both i.v. day 1 3-weekly for 8 cycles) as first line treatment with chemotherapy. Objective responses occurred in 17 patients out of 58 (29%) who received CMF and nine out of 58 (15%) who received MM; 95% confidence interval for difference in response rates (–1%–29%), P = 0.07. No statistically significant differences were seen in overall survival or time to progression between the two regimes although a tendency towards a shorter progression time on the MM regime must be acknowledged. There was, however, significantly reduced haematological toxicity (P < 0.001) and alopecia (P < 0.001) and fewer dose reductions and delays in patients randomized to MM. No statistically significant differences were seen between the two regimes in terms of quality of life (QOL). However, some association between QOL and toxicity was apparent overall with pooled QOL estimates tending to indicate a worsening in psychological state with increasing maximum toxicity over treatment. Despite the fact that results surrounding response rates and time to progression did not reach statistical significance, their possible compatibility with an improved outcome on CMF treatment must be borne in mind. However, MM is a well-tolerated regimen with fewer side-effects than CMF, which with careful patient management and follow-up, therefore, may merit consideration as a first-line treatment to palliate patients with metastatic breast cancer who are infirm or elderly. © 1999 Cancer Research Campaign

Keywords: breast cancer, chemotherapy, metastases, mitoxantrone, methotrexate

Full Text

The Full Text of this article is available as a PDF (74.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Weinberg V., Perloff M., Weiss R., Perry M., Korzun A., Ginsberg S., Holland J. F. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987 Oct;5(10):1523–1533. doi: 10.1200/JCO.1987.5.10.1523. [DOI] [PubMed] [Google Scholar]
  2. Bull J. M., Tormey D. C., Li S. H., Carbone P. P., Falkson G., Blom J., Perlin E., Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649–1657. doi: 10.1002/1097-0142(197805)41:5<1649::aid-cncr2820410501>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  3. Canellos G. P., DeVita V. T., Gold G. L., Chabner B. A., Schein P. S., Young R. C. Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med. 1976 Apr;84(4):389–392. doi: 10.7326/0003-4819-84-4-389. [DOI] [PubMed] [Google Scholar]
  4. Clavel M., Catimel G. Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer. 1993;29A(4):598–604. doi: 10.1016/s0959-8049(05)80161-3. [DOI] [PubMed] [Google Scholar]
  5. Cummings F. J., Gelman R., Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985 Jul;3(7):932–940. doi: 10.1200/JCO.1985.3.7.932. [DOI] [PubMed] [Google Scholar]
  6. Greenspan E. M. Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp N Y. 1966 Jan-Feb;33(1):1–27. [PubMed] [Google Scholar]
  7. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jodrell D. I., Smith I. E., Mansi J. L., Pearson M. C., Walsh G., Ashley S., Sinnett H. D., McKinna J. A. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer. 1991 May;63(5):794–798. doi: 10.1038/bjc.1991.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maguire P., Selby P. Assessing quality of life in cancer patients. Br J Cancer. 1989 Sep;60(3):437–440. doi: 10.1038/bjc.1989.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mouridsen H. T. Systemic therapy of advanced breast cancer. Drugs. 1992;44 (Suppl 4):17–69. doi: 10.2165/00003495-199200444-00003. [DOI] [PubMed] [Google Scholar]
  11. Payne S. A. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992 Dec;35(12):1505–1509. doi: 10.1016/0277-9536(92)90053-s. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Powles T. J., Jones A. L., Judson I. R., Hardy J. R., Ashley S. E. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991 Aug;64(2):406–410. doi: 10.1038/bjc.1991.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smalley R. V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209–220. doi: 10.1007/BF01803563. [DOI] [PubMed] [Google Scholar]
  15. Stein R. C., Bower M., Law M., Bliss J. M., Barton C., Gazet J. C., Ford H. T., Coombes R. C. Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. Eur J Cancer. 1992;28A(12):1963–1965. doi: 10.1016/0959-8049(92)90237-v. [DOI] [PubMed] [Google Scholar]
  16. Stewart D. J., Evans W. K., Shepherd F. A., Wilson K. S., Pritchard K. I., Trudeau M. E., Wilson J. J., Martz K. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol. 1997 May;15(5):1897–1905. doi: 10.1200/JCO.1997.15.5.1897. [DOI] [PubMed] [Google Scholar]
  17. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  18. Tormey D. C., Gelman R., Band P. R., Sears M., Rosenthal S. N., DeWys W., Perlia C., Rice M. A. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235–1244. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  19. Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. [DOI] [PubMed] [Google Scholar]
  20. de Haes J. C., van Knippenberg F. C., Neijt J. P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990 Dec;62(6):1034–1038. doi: 10.1038/bjc.1990.434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES